Recent executive actions have accelerated federal marijuana rescheduling efforts. In April 2026, following a December 2025 executive order, the Department of Justice and DEA moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. An expedited administrative hearing on broader rescheduling of all marijuana to Schedule III begins June 29, 2026, with procedural updates aimed at completing rulemaking more efficiently. These steps, building on prior HHS recommendations, represent the most direct recent catalysts shaping trader assessments of timelines. The hearing outcome and any subsequent rulemaking milestones within the coming months could further influence probabilities for resolution by specific dates this year.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour$762,057 Vol.
31 mars 2026
30 juin
3%
31 décembre
29%
$762,057 Vol.
30 juin
$338,583 Vol.
3%
31 décembre
$158,592 Vol.
29%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have accelerated federal marijuana rescheduling efforts. In April 2026, following a December 2025 executive order, the Department of Justice and DEA moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. An expedited administrative hearing on broader rescheduling of all marijuana to Schedule III begins June 29, 2026, with procedural updates aimed at completing rulemaking more efficiently. These steps, building on prior HHS recommendations, represent the most direct recent catalysts shaping trader assessments of timelines. The hearing outcome and any subsequent rulemaking milestones within the coming months could further influence probabilities for resolution by specific dates this year.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Marché ouvert : Feb 7, 2026, 5:04 PM ET
Volume
$762,057Date de fin
31 mars 2026Marché ouvert
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have accelerated federal marijuana rescheduling efforts. In April 2026, following a December 2025 executive order, the Department of Justice and DEA moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. An expedited administrative hearing on broader rescheduling of all marijuana to Schedule III begins June 29, 2026, with procedural updates aimed at completing rulemaking more efficiently. These steps, building on prior HHS recommendations, represent the most direct recent catalysts shaping trader assessments of timelines. The hearing outcome and any subsequent rulemaking milestones within the coming months could further influence probabilities for resolution by specific dates this year.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$762,057Date de fin
31 mars 2026Marché ouvert
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent executive actions have accelerated federal marijuana rescheduling efforts. In April 2026, following a December 2025 executive order, the Department of Justice and DEA moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. An expedited administrative hearing on broader rescheduling of all marijuana to Schedule III begins June 29, 2026, with procedural updates aimed at completing rulemaking more efficiently. These steps, building on prior HHS recommendations, represent the most direct recent catalysts shaping trader assessments of timelines. The hearing outcome and any subsequent rulemaking milestones within the coming months could further influence probabilities for resolution by specific dates this year.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes